Press release
Retinopathy of Prematurity (ROP) Market to Hit USD 1.7 Billion by 2034
Retinopathy of Prematurity (ROP)
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72279
With advances in neonatal intensive care units (NICUs), survival rates of premature infants have improved worldwide - but this has also led to a higher incidence of ROP. The market is expanding with the growing use of anti-VEGF agents, laser photocoagulation, and tele-ophthalmology screening, as well as research into long-acting biologics and gene therapy for retinal diseases.
Market Overview
• Market Size (2024): USD 786 million
• Forecast (2034): USD 1.7 billion
• CAGR (2025-2034): 8.0%
Key Highlights:
• Rising global premature birth rates fueling ROP prevalence.
• Increasing adoption of anti-VEGF injections (ranibizumab, bevacizumab, aflibercept).
• Laser photocoagulation remains widely used but biologics are rapidly gaining share.
• Growing role of AI-powered tele-retinal screening in NICUs.
Segmentation Analysis
By Treatment Type:
• Laser Photocoagulation (standard therapy, cost-effective)
• Anti-VEGF Therapies
o Bevacizumab (off-label)
o Ranibizumab
o Aflibercept
• Combination Therapy (laser + anti-VEGF)
• Adjunctive/Supportive Care (oxygen management, monitoring)
• Emerging Therapies (gene therapy, regenerative medicine)
By Stage of Disease:
• Mild ROP (observation/monitoring)
• Moderate ROP (anti-VEGF or laser therapy)
• Severe ROP (combination therapy, surgery for retinal detachment)
By End Use:
• Hospitals & NICUs
• Specialty Eye Clinics
• Tele-ophthalmology & Screening Programs
• Academic & Research Institutes
Segmentation Summary:
Laser therapy remains the mainstay of ROP management, but anti-VEGF agents are the fastest-growing treatment segment, offering precision and reduced collateral damage.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72279/retinopathy-of-prematurity-market
Regional Analysis
North America
• Largest market (~41% share in 2024).
• High NICU survival rates increasing ROP cases.
• Strong adoption of anti-VEGF biologics and AI-based screening.
Europe
• ~30% share.
• Germany, UK, and France lead in NICU-based ROP care.
• EMA approvals supporting biologic adoption.
Asia-Pacific
• Fastest-growing region, CAGR ~9.2%.
• Largest premature birth rates globally, especially in India and China.
• Rising demand for tele-ophthalmology programs to address rural patient populations.
Latin America
• Brazil and Mexico expanding ROP screening and treatment infrastructure.
Middle East & Africa
• GCC countries improving neonatal care facilities.
• High unmet need in African nations due to limited NICU and ophthalmology capacity.
Regional Summary:
North America and Europe lead adoption today, but Asia-Pacific will drive fastest growth, given its high premature birth rates and increasing access to advanced therapies.
Market Dynamics
Key Growth Drivers:
• Rising premature birth rates worldwide.
• Expanding access to anti-VEGF therapies and advanced NICUs.
• Growing use of AI-driven tele-ophthalmology for ROP screening.
• Strong pipeline of next-generation biologics and regenerative treatments.
Key Challenges:
• Limited awareness and screening access in low-income regions.
• High treatment costs of anti-VEGF biologics.
• Risk of systemic side effects in neonates from intravitreal injections.
• Shortage of pediatric retina specialists in many countries.
Latest Trends:
• Development of long-acting anti-VEGF formulations for infants.
• AI-based predictive models for ROP progression risk.
• Growing integration of telemedicine in NICUs.
• Clinical trials in gene therapy and regenerative medicine for retinal vascular repair.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72279
Competitor Analysis
Major Players in the Market:
• Novartis AG (Lucentis - ranibizumab)
• Regeneron Pharmaceuticals, Inc. (Eylea - aflibercept)
• Roche Holding AG (faricimab pipeline)
• Bayer AG
• Pfizer Inc.
• Bausch + Lomb
• Santen Pharmaceutical Co., Ltd.
• Allergan (AbbVie Inc.)
• Eyepoint Pharmaceuticals, Inc.
• Academic and biotech startups advancing neonatal retina research
Competitive Summary:
Novartis and Regeneron dominate anti-VEGF therapies for ROP, while Roche is advancing dual-pathway biologics. Bausch and Santen provide ophthalmic support solutions, while biotech innovators explore long-acting biologics and gene therapy approaches.
Conclusion
The Retinopathy of Prematurity (ROP) Market, valued at USD 786 million in 2024, is projected to reach USD 1.7 billion by 2034, growing at a CAGR of 8.0%.
Key Takeaways:
• Premature birth trends drive the global ROP burden.
• Laser therapy dominates today, but anti-VEGF agents are growing fastest.
• North America and Europe lead adoption, while Asia-Pacific experiences the highest growth.
• AI-based tele-screening, long-acting biologics, and gene therapy represent the future of ROP management.
Over the next decade, the ROP market will shift toward precision biologics, AI-driven early detection, and regenerative approaches, significantly improving vision outcomes for premature infants worldwide.
This report is also available in the following languages : Japanese (未熟児網膜症市場), Korean (미숙아 망막병증 시장), Chinese (早产儿视网膜病变市场), French (Marché de la rétinopathie du prématuré), German (Markt für Frühgeborenen-Retinopathie), and Italian (Mercato della retinopatia del prematuro), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72279/retinopathy-of-prematurity-market#request-a-sample
Our More Reports:
Glycan Analysis Market
https://exactitudeconsultancy.com/reports/72860/glycan-analysis-market
CRISPR Gene Editing Therapies Market
https://exactitudeconsultancy.com/reports/72861/crispr-gene-editing-therapies-market
Drug Discovery Platforms Market
https://exactitudeconsultancy.com/reports/72862/drug-discovery-platforms-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinopathy of Prematurity (ROP) Market to Hit USD 1.7 Billion by 2034 here
News-ID: 4194160 • Views: …
More Releases from Exactitude Consultancy
Radiation Retinopathy Market to Reach USD 1.3 Billion by 2034
Radiation retinopathy is a progressive microangiopathy of the retina caused by exposure to ionizing radiation, typically following ocular, orbital, or head-and-neck radiotherapy. It often presents months to years after treatment with retinal hemorrhages, microaneurysms, cotton wool spots, and macular edema, leading to gradual vision loss.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72277
As cancer survival rates improve due to advances in radiotherapy, the incidence of radiation retinopathy is increasing.…
Scleritis Market to Reach USD 2.2 Billion by 2034
Scleritis is a serious inflammatory disease of the sclera, the white outer coating of the eye. It is often associated with systemic autoimmune conditions such as rheumatoid arthritis, granulomatosis with polyangiitis, lupus, and inflammatory bowel disease. Symptoms include severe ocular pain, redness, and potential vision loss if untreated.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72281
Unlike episcleritis, scleritis is more severe and frequently requires systemic immunosuppressive therapy or biologics.…
Ophthalmic Imaging Equipment Market Expected to Grow at 7.6% CAGR
Introduction
Ophthalmic imaging equipment plays a vital role in the diagnosis, monitoring, and treatment planning of various eye diseases such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, cataracts, and corneal disorders. These devices allow clinicians to visualize ocular structures with high precision, enabling earlier detection and improved management of sight-threatening conditions.
With the rising global burden of eye disorders and an aging population, the demand for optical coherence tomography (OCT), fundus…
X-Linked Retinoschisis (XLRS) Market is expected to reach USD 912 million by 203 …
X-linked retinoschisis (XLRS) is a rare inherited retinal disorder affecting males, caused by mutations in the RS1 gene. It leads to splitting of the retinal layers, resulting in impaired central vision, reduced visual acuity, and in some cases, retinal detachment. Symptoms typically present in childhood or early adolescence, often affecting school performance and quality of life.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72283
With no approved curative therapy, current…
More Releases for ROP
Retinopathy of Prematurity Therapeutics Market: Early-Stage Pipeline and FDA Des …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others.
DelveInsight's "Retinopathy of Prematurity Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/retinopathy-of-prematurity-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of ROP, historical and forecasted epidemiology, as well…
Retinopathy of Prematurity Market Driven by Rising Preterm Births and Advancemen …
✅ Retinopathy of Prematurity Market: Rising Incidence of Premature Births Fuels Demand for Advanced Treatments
The Retinopathy of Prematurity (ROP) Market is gaining significant traction owing to the increasing number of premature births worldwide and heightened awareness among healthcare providers and parents regarding early screening and treatment. ROP is a potentially blinding eye disorder primarily affecting premature infants born before 31 weeks of gestation. The global market for ROP is poised…
Retinopathy of Prematurity Market, Advancements in Early Detection and Treatment …
Overview of the Market
The Retinopathy of Prematurity (ROP) market is poised for significant growth in the coming years. Retinopathy of Prematurity is a severe eye disease that primarily affects premature infants, often leading to blindness if left untreated. The market for ROP treatments has grown substantially as awareness of this condition increases, alongside advancements in diagnostic and therapeutic solutions. As neonatal care improves globally, the demand for ROP-related treatments, including…
Retinopathy of Prematurity Market is Expected to Witness Significant Growth from …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others. This growth trajectory is further supported by the rising awareness, improvements in neonatal care units, and increasing focus on preventive approaches.
DelveInsight's "Retinopathy of Prematurity Market…
Global Newborn Eye Imaging Systems Market Outlook 2025-2034: Trends, Innovations …
The Newborn Eye Imaging Systems Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Newborn Eye Imaging Systems Market Size During the Forecast Period?
In recent times, there has been a robust growth in the market size of newborn eye imaging systems. The…
Dr. Mangat Ram Dogra from Grewal Eye Institute Honored with Dr. Badrinath Oratio …
Chandigarh's renowned retina specialist Dr. Mangat Ram Dogra, currently working as the Director of Retina Services at Grewal Eye Institute, has been honoured with the prestigious Dr. Badrinath Oration at the 32nd conference of Vitro-retinal Society of India (VRSI) 2023, at Thiruvananthapuram. This distinguished award recognises Dr. Dogra's lifelong dedication to combating Retinopathy of Prematurity (ROP). ROP is a disease of retina in premature babies and if not diagnosed and…
